Resultados de procura - Jia-Lin Lee
- Mostrando 1 - 16 Resultados de 16
-
1
-
2
-
3
-
4
-
5
-
6
Osteopontin Promotes Integrin Activation through Outside-In and Inside-Out Mechanisms: OPN-CD44V Interaction Enhances Survival in Gastrointestinal Cancer Cells por Jia-Lin Lee, Mei-Jung Wang, Putty‐Reddy Sudhir, Gen-Der Chen, Chin‐Wen Chi, Jeou-Yuan Chen
Publicado 2007Artigo -
7
-
8
-
9
Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties por Ying-Jhen Su, Wei‐Hsin Lin, Yi‐Wen Chang, Kuo‐Chen Wei, Chi-Lung Liang, Shin‐Cheh Chen, Jia-Lin Lee
Publicado 2015Artigo -
10
-
11
Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum por Dok Hyun Yoon, M.-H. Ryu, Y S Park, Heon‐Jin Lee, C Lee, B-Y. Ryoo, Jia-Lin Lee, H.-M. Chang, T W Kim, Y-K. Kang
Publicado 2012Artigo -
12
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer por Changhoon Yoo, Jenn-Jiang Hwang, Je Hyeong Kim, T W Kim, J S Lee, D H Park, S S Lee, Dong Wan Seo, S K Lee, MH Kim, Dongjin Han, Sung‐Cheol Kim, Jia-Lin Lee
Publicado 2009Artigo -
13
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer por Jia-Lin Lee, Y-K. Kang, Hye Jin Kang, KH Lee, Dae Young Zang, B-Y. Ryoo, J G Kim, S R Park, Wonseok Kang, D.B. Shin, M.-H. Ryu, Heung-Moon Chang, Tae‐Won Kim, Jin Ho Baek, Young Joo Min
Publicado 2008Artigo -
14
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial por Marine Gross‐Goupil, Tae‐Geon Kwon, Masatoshi Eto, Dingwei Ye, Hideaki Miyake, S.I. Seo, S.-S. Byun, Jia-Lin Lee, Viraj A. Master, Jie Jin, R. DeBenedetto, R. Linke, Michelle Casey, Brad Rosbrook, Mariajosé Lechuga, Olga Valota, Enrique Grande, David I. Quinn
Publicado 2018Artigo -
15
697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally... por Thomas Powles, Michiel S. van der Heijden, D. Castellano Gauna, Yohann Loriot, Matt D. Galsky, Daniel P. Petrylak, Osamu Ogawa, S.H. Park, Andrea Necchi, Jia-Lin Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, André P. Fay, Ignacio Durán, Natasha Angra, Amod Gupta, Pengcheng He, William P. Levin, Joaquim Bellmunt
Publicado 2020Artigo -
16
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up por Arjun Vasant Balar, Daniel Castellano, Petros Grivas, David J. Vaughn, Thomas Powles, Jacqueline Vuky, Yves Fradet, Jia-Lin Lee, Lawrence Fong, Nicholas J. Vogelzang, José A. Martínez-Climent, Andrea Necchi, Daniel P. Petrylak, Elizabeth R. Plimack, Jin Xu, Kazuo Imai, Blanca Homet Moreno, Joaquim Bellmunt, Ronald de Wit, Peter H. O’Donnell
Publicado 2022Artigo
Ferramentas de procura:
Materias Relacionadas
Cancer
Biology
Cell biology
Cancer research
Genetics
Internal medicine
Medicine
Signal transduction
Cancer stem cell
Cell
Stem cell
Biochemistry
Oncology
Chemotherapy
Gastroenterology
Surgery
Wnt signaling pathway
Carcinogenesis
Clinical endpoint
Environmental health
Epithelial–mesenchymal transition
Integrin
Metastasis
Population
Bladder cancer
CD44
Catenin
Cell culture
Clinical trial
Colorectal cancer